PROGEN - passion for research


anti-AAV2 (intact particle) mouse monoclonal, A20, supernatant concentrate

Specifically detects intact virus particles, both empty and full capsids. With AAV-2 and AAV-3 A20 recognizes a conformational epitope of assembled capsids, not present in denatured and native unassembled capsid proteins. Not for WB.
Cat. No.: 65255
Quantity:  100 µL

Delivery Time: usually 1-7 working days

Excl. 19% Tax, excl. Shipping Cost

Call us now for more information on our products: +49 6221 8278-0

Any more questions?


Product description

Host mouse
Antibody Type monoclonal
Isotype IgG3
Clone A20
Immunogen adeno-associated virus 2 capsid proteins and virus particles
Purification hybridoma cell culture supernatant concentrate
Conjugate unconjugated
Formulation contains 0.09% sodium azide
Storage short term at 2 – 8 °C; long term storage in aliquots at - 20 °C; avoid freeze/ thaw cycles
Tested species reactivity AAV2, AAV3


Affinity Chromatography assay dependent
ELISA assay dependent
Immunocytochemistry (ICC)/ Immunofluorescence (IF) assay dependent
Immunohistochemistry (IHC) - frozen assay dependent
Immunohistochemistry (IHC) - paraffin assay dependent
Immunoprecipitation (IP) assay dependent
Neutralization Assay assay dependent



For characterization of different stages of infection and very useful for the analysis of Specificity the AAV2 assembly process. A20 specifically reacts with intact adeno-associated virus 2 particles, empty and full capsids. Recognizes a conformational epitope of assembled capsids, not present in denatured capsid proteins and native but unassembled capsid proteins. The antibody cannot be used for immunoblotting. Epitope mapping experiments (Wobus, C. E. et al., 2000 ) identified four immunoreactive (discontinous) regions. The major reaction was attributed to sequence aa 369 to aa 378 of AAV2 capsids. The antibody is also useful for neutralizing experiments (Moskalenko, M. et al., 2000).



  1. Mietzsch, M. et al. OneBac: Platform for Scalable and High-Titer Production of Adeno-Associated Virus Serotype 1–12 Vectors for Gene Therapy. Hum. Gene Ther. 25, 212–222 (2014).
  2. Naumer, M. et al. Properties of the Adeno-Associated Virus Assembly-Activating Protein. J. Virol. 86, 13038–13048 (2012).
  3. Moskalenko, M. et al. Epitope Mapping of Human Anti-Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene Therapy and Virus Structure. Jounal Virol. 74, 1761–1766 (2000).
  4. Wobus, C. E. et al. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74, 9281–93 (2000).
  5. Grimm, D. et al. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6, 1322–30 (1999).
  6. Bartlett, J. S., Kleinschmidt, J., Boucher, R. C. & Samulski, R. J. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab’gamma)2 antibody. Nat. Biotechnol. 17, 181–6 (1999).
  7. Wistuba, A. et al. Subcellular Compartmentalization of Adeno-Associated Virus Type 2 Assembly. J. Virol. 71, 1341–1352 (1997).
  8. Wistuba, A., Weger, S., Kern, A., Rgen, J. & Kleinschmidt, A. Intermediates of Adeno-Associated Virus Type 2 Assembly: Identification of Soluble Complexes Containing Rep and Cap Proteins. J. Virol. 69, 5311–5319 (1995).


Material safety data sheet

Please complete the form below to request a material safety data sheet

Personal Info

* Required Fields

Product Request

Personal Info

* Required Fields